PT3122378T - Antigénios estafilocócicos mutantes - Google Patents

Antigénios estafilocócicos mutantes

Info

Publication number: PT3122378T
Authority: PT; Portugal
Prior art keywords: staphylococcal antigens; mutant staphylococcal; mutant; antigens; staphylococcal
Prior art date: 2014-03-26

Application number

PT157115239T

Other languages

English (en)

Original Assignee

Glaxosmithkline Biologicals Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-03-26

Filing date

2015-03-24

Publication date

2020-03-04

2015-03-24 Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa

2020-03-04 Publication of PT3122378T publication Critical patent/PT3122378T/pt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
- A61K2039/645—Dendrimers; Multiple antigen peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Mycology (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Biophysics (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Communicable Diseases (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)

PT157115239T 2014-03-26 2015-03-24 Antigénios estafilocócicos mutantes PT3122378T (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP14161861		2014-03-26
EP14192913		2014-11-12

Publications (1)

Publication Number	Publication Date
PT3122378T true PT3122378T (pt)	2020-03-04

Family

ID=52706188

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT157115239T PT3122378T (pt)	2014-03-26	2015-03-24	Antigénios estafilocócicos mutantes

Country Status (25)

Country	Link
US (1)	US10328140B2 (pt)
EP (2)	EP3639850A1 (pt)
JP (2)	JP6894237B2 (pt)
KR (3)	KR102297357B1 (pt)
CN (2)	CN106103469B (pt)
AU (1)	AU2015238512B2 (pt)
BE (2)	BE1022857A1 (pt)
CA (1)	CA2942450A1 (pt)
CY (1)	CY1122537T1 (pt)
DK (1)	DK3122378T3 (pt)
EA (1)	EA037818B1 (pt)
ES (1)	ES2769647T3 (pt)
HR (1)	HRP20200217T1 (pt)
HU (1)	HUE047808T2 (pt)
IL (2)	IL247328B (pt)
LT (1)	LT3122378T (pt)
MX (1)	MX377794B (pt)
PL (1)	PL3122378T3 (pt)
PT (1)	PT3122378T (pt)
RS (1)	RS59971B1 (pt)
SG (1)	SG11201606887WA (pt)
SI (1)	SI3122378T1 (pt)
SM (1)	SMT202000085T1 (pt)
WO (2)	WO2015144653A1 (pt)
ZA (1)	ZA201605818B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2847204A1 (en) *	2011-09-01	2013-03-07	Novartis Ag	Adjuvanted formulations of staphylococcus aureus antigens
BR112018073690B1 (pt) *	2016-05-16	2022-05-24	Infectious Disease Research Institute	Formulação contendo agonista de tlr e métodos de uso
GB201802339D0 (en)	2018-02-13	2018-03-28	Glaxosmithkline Biologicals Sa	Immunogenic composition
CN109526985B (zh) *	2018-11-19	2021-03-12	黑龙江省农垦科学院	土地类芽胞杆菌蛋白EsxA作为水稻稻瘟病生物防治剂的应用
AU2020273471A1 (en)	2019-05-14	2021-12-23	The University Of Chicago	Methods and compositions comprising Staphylococcus protein A (SpA) variants
EP3777884A1 (en)	2019-08-15	2021-02-17	GlaxoSmithKline Biologicals S.A.	Immunogenic composition
US20220362368A1 (en)	2019-10-02	2022-11-17	Janssen Vaccines & Prevention B.V.	Staphylococcus peptides and methods of use
CN118480136B (zh) *	2024-06-19	2025-01-14	南京澄实生物医药科技有限公司	一种预防和治疗金黄色葡萄球菌感染的免疫原性组合物

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE8205892D0 (sv)	1982-10-18	1982-10-18	Bror Morein	Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
DE3485094D1 (de)	1983-01-25	1991-10-31	Ciba Geigy Ag	Neue peptidderivate.
IL73534A (en)	1983-11-18	1990-12-23	Riker Laboratories Inc	1h-imidazo(4,5-c)quinoline-4-amines,their preparation and pharmaceutical compositions containing certain such compounds
US4680338A (en)	1985-10-17	1987-07-14	Immunomedics, Inc.	Bifunctional linker
US5057540A (en)	1987-05-29	1991-10-15	Cambridge Biotech Corporation	Saponin adjuvant
US5238944A (en)	1988-12-15	1993-08-24	Riker Laboratories, Inc.	Topical formulations and transdermal delivery systems containing 1-isobutyl-1H-imidazo[4,5-c]quinolin-4-amine
US4929624A (en)	1989-03-23	1990-05-29	Minnesota Mining And Manufacturing Company	Olefinic 1H-imidazo(4,5-c)quinolin-4-amines
HU212924B (en)	1989-05-25	1996-12-30	Chiron Corp	Adjuvant formulation comprising a submicron oil droplet emulsion
US4988815A (en)	1989-10-26	1991-01-29	Riker Laboratories, Inc.	3-Amino or 3-nitro quinoline compounds which are intermediates in preparing 1H-imidazo[4,5-c]quinolines
JP2955019B2 (ja)	1991-03-01	1999-10-04	ミネソタマイニングアンドマニュファクチャリングカンパニー	１−置換、２−置換１Ｈ−イミダゾ〔４，５−ｃ〕キノリン−４−アミン
US5389640A (en)	1991-03-01	1995-02-14	Minnesota Mining And Manufacturing Company	1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5268376A (en)	1991-09-04	1993-12-07	Minnesota Mining And Manufacturing Company	1-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5266575A (en)	1991-11-06	1993-11-30	Minnesota Mining And Manufacturing Company	2-ethyl 1H-imidazo[4,5-ciquinolin-4-amines
IL105325A (en)	1992-04-16	1996-11-14	Minnesota Mining & Mfg	Immunogen/vaccine adjuvant composition
US5395937A (en)	1993-01-29	1995-03-07	Minnesota Mining And Manufacturing Company	Process for preparing quinoline amines
US5776468A (en)	1993-03-23	1998-07-07	Smithkline Beecham Biologicals (S.A.)	Vaccine compositions containing 3-0 deacylated monophosphoryl lipid A
US5352784A (en)	1993-07-15	1994-10-04	Minnesota Mining And Manufacturing Company	Fused cycloalkylimidazopyridines
ES2149276T3 (es)	1993-07-15	2000-11-01	Minnesota Mining & Mfg	Imidazo(4,5-c)piridin-4-aminas.
AU5543294A (en)	1993-10-29	1995-05-22	Pharmos Corp.	Submicron emulsions as vaccine adjuvants
GB9326174D0 (en)	1993-12-22	1994-02-23	Biocine Sclavo	Mucosal adjuvant
US6429199B1 (en)	1994-07-15	2002-08-06	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules for activating dendritic cells
US6207646B1 (en)	1994-07-15	2001-03-27	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
US6239116B1 (en)	1994-07-15	2001-05-29	University Of Iowa Research Foundation	Immunostimulatory nucleic acid molecules
AUPM873294A0 (en)	1994-10-12	1994-11-03	Csl Limited	Saponin preparations and use thereof in iscoms
US5482936A (en)	1995-01-12	1996-01-09	Minnesota Mining And Manufacturing Company	Imidazo[4,5-C]quinoline amines
UA56132C2 (uk)	1995-04-25	2003-05-15	Смітклайн Бічем Байолоджікалс С.А.	Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
DK1005368T3 (da)	1997-03-10	2010-01-04	Ottawa Hospital Res Inst	Anvendelse af nukleinsyrer, der indeholder ikke-metyleret CpG dinukleotid i kombination med alun som hjælpestoffer
US6818222B1 (en)	1997-03-21	2004-11-16	Chiron Corporation	Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
ATE278419T1 (de) *	1997-04-01	2004-10-15	Corixa Corp	Wässerige immunologische adjuvantzusammensetzungen aus monophosphoryllipid a
US6080725A (en)	1997-05-20	2000-06-27	Galenica Pharmaceuticals, Inc.	Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
US6562798B1 (en)	1998-06-05	2003-05-13	Dynavax Technologies Corp.	Immunostimulatory oligonucleotides with modified bases and methods of use thereof
US6110929A (en)	1998-07-28	2000-08-29	3M Innovative Properties Company	Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof
GB9817052D0 (en)	1998-08-05	1998-09-30	Smithkline Beecham Biolog	Vaccine
CN100406060C (zh)	1998-10-16	2008-07-30	史密丝克莱恩比彻姆生物有限公司	一种佐剂组合物
JP4413435B2 (ja)	1998-10-22	2010-02-10	陽介内藤	シャワーヘッド
US20030130212A1 (en)	1999-01-14	2003-07-10	Rossignol Daniel P.	Administration of an anti-endotoxin drug by intravenous infusion
US6551600B2 (en)	1999-02-01	2003-04-22	Eisai Co., Ltd.	Immunological adjuvant compounds compositions and methods of use thereof
PT1150918E (pt)	1999-02-03	2005-01-31	Biosante Pharmaceuticals Inc	Metodo de fabrico de particulas terapeuticas de fosfato de calcio
US6331539B1 (en)	1999-06-10	2001-12-18	3M Innovative Properties Company	Sulfonamide and sulfamide substituted imidazoquinolines
WO2002026757A2 (en)	2000-09-26	2002-04-04	Hybridon, Inc.	Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes
US6667312B2 (en)	2000-12-08	2003-12-23	3M Innovative Properties Company	Thioether substituted imidazoquinolines
US6677348B2 (en)	2000-12-08	2004-01-13	3M Innovative Properties Company	Aryl ether substituted imidazoquinolines
US6664264B2 (en)	2000-12-08	2003-12-16	3M Innovative Properties Company	Thioether substituted imidazoquinolines
US6660735B2 (en)	2000-12-08	2003-12-09	3M Innovative Properties Company	Urea substituted imidazoquinoline ethers
US6664260B2 (en)	2000-12-08	2003-12-16	3M Innovative Properties Company	Heterocyclic ether substituted imidazoquinolines
US6660747B2 (en)	2000-12-08	2003-12-09	3M Innovative Properties Company	Amido ether substituted imidazoquinolines
US6664265B2 (en)	2000-12-08	2003-12-16	3M Innovative Properties Company	Amido ether substituted imidazoquinolines
US6677347B2 (en)	2000-12-08	2004-01-13	3M Innovative Properties Company	Sulfonamido ether substituted imidazoquinolines
UA74852C2 (en)	2000-12-08	2006-02-15	3M Innovative Properties Co	Urea-substituted imidazoquinoline ethers
WO2003035836A2 (en)	2001-10-24	2003-05-01	Hybridon Inc.	Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
US6677349B1 (en)	2001-12-21	2004-01-13	3M Innovative Properties Company	Sulfonamide and sulfamide substituted imidazoquinolines
WO2003101949A2 (en)	2002-05-29	2003-12-11	3M Innovative Properties Company	Process for imidazo[4,5-c]pyridin-4-amines
DK1742659T3 (da)	2004-04-05	2013-06-03	Zoetis P Llc	Mikrofluidiserede olie-i-vand-emulsioner og vaccinesammensætninger
CN101175508A (zh) *	2004-10-21	2008-05-07	惠氏公司	表皮葡萄球菌多肽抗原的免疫原性组合物
US20060228369A1 (en)	2005-04-11	2006-10-12	Program For Appropriate Technology In Health	Stabilization and preservation of temperature-sensitive vaccines
US7691368B2 (en)	2005-04-15	2010-04-06	Merial Limited	Vaccine formulations
US8703095B2 (en)	2005-07-07	2014-04-22	Sanofi Pasteur S.A.	Immuno-adjuvant emulsion
TWI382019B (zh)	2005-08-19	2013-01-11	Array Biopharma Inc	作為類鐸受體（ｔｏｌｌ-ｌｉｋｅｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯
GB0526038D0 (en)	2005-12-21	2006-02-01	Glaxosmithkline Biolog Sa	Immunogenic composition
FR2896162B1 (fr)	2006-01-13	2008-02-15	Sanofi Pasteur Sa	Emulsion huile dans eau thermoreversible
KR20090019007A (ko)	2006-06-12	2009-02-24	나비 바이오파마슈티컬즈	스타필로코쿠스 감염증을 치료 및 예방하기 위한 알파-독소의 용도
JP5356228B2 (ja)	2006-07-07	2013-12-04	ギリアードサイエンシーズ，インコーポレイテッド	ｔｏｌｌ様レセプター７の調節因子
WO2008043774A1 (en)	2006-10-12	2008-04-17	Glaxosmithkline Biologicals S.A.	Vaccine comprising an oil in water emulsion adjuvant
US20090007256A1 (en)	2007-06-28	2009-01-01	Microsoft Corporation	Using a trusted entity to drive security decisions
EP2666784B1 (en)	2007-08-31	2017-04-05	University Of Chicago	Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
PE20091236A1 (es)	2007-11-22	2009-09-16	Astrazeneca Ab	Derivados de pirimidina como immunomoduladores de tlr7
HRP20150892T1 (hr)	2008-03-03	2015-09-25	Novartis Ag	Spojevi i sastavi kao modulatori tlr-aktivnosti
CN101980707B (zh)	2008-03-24	2015-05-20	4Sc股份有限公司	新的取代的咪唑并喹啉化合物
EP2313111B1 (en)	2008-08-01	2013-09-04	Ventirx Pharmaceuticals, Inc.	Toll-like receptor agonist formulations and their use
EP2208787A1 (en) *	2009-01-19	2010-07-21	Université de Liège	A recombinant alpha-hemolysin polypeptide of Staphylococcus aureus, having a deletion in the stem domain and heterologous sequences inserted
PL3281947T3 (pl) *	2009-04-03	2020-07-27	The University Of Chicago	Kompozycje i sposoby związane z wariantami białka A (SpA)
SG175092A1 (en) *	2009-04-14	2011-11-28	Novartis Ag	Compositions for immunising against staphylococcus aerus
US9950062B2 (en)	2009-09-02	2018-04-24	Glaxosmithkline Biologicals Sa	Compounds and compositions as TLR activity modulators
EP2555794A4 (en)	2010-04-05	2014-01-15	Univ Chicago	COMPOSITIONS AND METHODS RELATING TO PROTEIN A (SPA) ANTIBODIES AS IMMUNE REACTION AMPLIFIERS
CN103313725B (zh)	2010-09-01	2016-06-29	诺华有限公司	免疫增强剂吸附不溶性金属离子
JP5793194B2 (ja)	2010-09-09	2015-10-14	ザ・ユニバーシティ・オブ・シカゴＴｈｅＵｎｉｖｅｒｓｉｔｙＯｆＣｈｉｃａｇｏ	感染防御ブドウ球菌抗原が関与する方法および組成物
CA2847204A1 (en)	2011-09-01	2013-03-07	Novartis Ag	Adjuvanted formulations of staphylococcus aureus antigens
WO2013092985A1 (en)	2011-12-23	2013-06-27	Novartis Ag	Stable compositions for immunising against staphylococcus aureus
JP6325986B2 (ja)	2012-03-07	2018-05-16	ノバルティスアーゲー	免疫学的に有用なアルギニン塩
MX372965B (es)	2012-03-08	2020-04-01	Glaxosmithkline Biologicals Sa	Formulaciones adyuvadas de vacunas de difteria, tetanos y tos ferina (dtp) de refuerzo.
WO2014033191A1 (en)	2012-08-31	2014-03-06	Novartis Ag	Stabilised proteins for immunising against staphylococcus aureus
WO2014033193A1 (en) *	2012-08-31	2014-03-06	Novartis Ag	Stabilised proteins for immunising against staphylococcus aureus
EP2890394B1 (en)	2012-08-31	2019-05-01	GlaxoSmithKline Biologicals SA	Stabilised proteins for immunising against staphylococcus aureus
CN104736165A (zh)	2012-08-31	2015-06-24	诺华股份有限公司	用于针对金黄色葡萄球菌的免疫的稳定化的蛋白质
CN103694322B (zh) *	2013-12-09	2016-08-17	成都欧林生物科技股份有限公司	金黄色葡萄球菌SpA5突变体及其制备方法和应用
CN103645318B (zh) *	2013-12-09	2016-11-02	成都欧林生物科技股份有限公司	金黄色葡萄球菌SpA5突变体抗原特异性IgG抗体检测方法和检测试剂盒

2015
- 2015-03-24 HU HUE15711523A patent/HUE047808T2/hu unknown
- 2015-03-24 WO PCT/EP2015/056175 patent/WO2015144653A1/en not_active Ceased
- 2015-03-24 EP EP19211691.1A patent/EP3639850A1/en not_active Withdrawn
- 2015-03-24 CA CA2942450A patent/CA2942450A1/en active Pending
- 2015-03-24 US US15/127,537 patent/US10328140B2/en active Active
- 2015-03-24 CN CN201580014701.3A patent/CN106103469B/zh active Active
- 2015-03-24 LT LTEP15711523.9T patent/LT3122378T/lt unknown
- 2015-03-24 ES ES15711523T patent/ES2769647T3/es active Active
- 2015-03-24 KR KR1020197027986A patent/KR102297357B1/ko not_active Expired - Fee Related
- 2015-03-24 RS RS20200215A patent/RS59971B1/sr unknown
- 2015-03-24 BE BE20155175A patent/BE1022857A1/fr not_active IP Right Cessation
- 2015-03-24 BE BE2015/5176A patent/BE1022744B1/fr not_active IP Right Cessation
- 2015-03-24 KR KR1020197010177A patent/KR102027429B1/ko not_active Expired - Fee Related
- 2015-03-24 AU AU2015238512A patent/AU2015238512B2/en not_active Ceased
- 2015-03-24 SI SI201531080T patent/SI3122378T1/sl unknown
- 2015-03-24 CN CN202011253615.7A patent/CN112521464A/zh active Pending
- 2015-03-24 PL PL15711523T patent/PL3122378T3/pl unknown
- 2015-03-24 MX MX2016012538A patent/MX377794B/es active IP Right Grant
- 2015-03-24 DK DK15711523.9T patent/DK3122378T3/da active
- 2015-03-24 PT PT157115239T patent/PT3122378T/pt unknown
- 2015-03-24 EA EA201691502A patent/EA037818B1/ru unknown
- 2015-03-24 EP EP15711523.9A patent/EP3122378B1/en active Active
- 2015-03-24 SM SM20200085T patent/SMT202000085T1/it unknown
- 2015-03-24 SG SG11201606887WA patent/SG11201606887WA/en unknown
- 2015-03-24 HR HRP20200217TT patent/HRP20200217T1/hr unknown
- 2015-03-24 WO PCT/EP2015/056179 patent/WO2015144655A1/en not_active Ceased
- 2015-03-24 JP JP2016558699A patent/JP6894237B2/ja not_active Expired - Fee Related
- 2015-03-24 KR KR1020167028541A patent/KR20160132109A/ko not_active Ceased
2016
- 2016-08-17 IL IL247328A patent/IL247328B/en active IP Right Grant
- 2016-08-22 ZA ZA2016/05818A patent/ZA201605818B/en unknown
2020
- 2020-01-30 CY CY20201100078T patent/CY1122537T1/el unknown
- 2020-10-15 JP JP2020173955A patent/JP2021035950A/ja active Pending
2021
- 2021-04-06 IL IL282104A patent/IL282104A/en unknown

Also Published As

Publication number	Publication date
KR102027429B1 (ko)	2019-10-01
JP6894237B2 (ja)	2021-06-30
EP3122378B1 (en)	2019-12-11
SI3122378T1 (sl)	2020-03-31
DK3122378T3 (da)	2020-03-02
IL282104A (en)	2021-05-31
HUE047808T2 (hu)	2020-05-28
WO2015144653A1 (en)	2015-10-01
JP2017511312A (ja)	2017-04-20
KR20160132109A (ko)	2016-11-16
LT3122378T (lt)	2020-02-10
EA037818B1 (ru)	2021-05-25
US20170143816A1 (en)	2017-05-25
JP2021035950A (ja)	2021-03-04
SMT202000085T1 (it)	2020-03-13
ZA201605818B (en)	2022-05-25
AU2015238512A1 (en)	2016-10-13
CN106103469B (zh)	2020-11-27
RS59971B1 (sr)	2020-03-31
EP3639850A1 (en)	2020-04-22
CA2942450A1 (en)	2015-10-01
MX377794B (es)	2025-03-10
EP3122378A1 (en)	2017-02-01
AU2015238512B2 (en)	2018-02-01
BE1022857A1 (fr)	2016-09-27
CY1122537T1 (el)	2021-01-27
US10328140B2 (en)	2019-06-25
ES2769647T3 (es)	2020-06-26
SG11201606887WA (en)	2016-09-29
BE1022744A1 (fr)	2016-08-29
BE1022744B1 (fr)	2016-08-29
HRP20200217T1 (hr)	2020-05-15
KR20190110655A (ko)	2019-09-30
US20180064800A9 (en)	2018-03-08
IL247328B (en)	2021-04-29
PL3122378T3 (pl)	2020-06-01
KR102297357B1 (ko)	2021-09-02
BR112016022011A2 (pt)	2017-10-24
WO2015144655A1 (en)	2015-10-01
KR20190040101A (ko)	2019-04-16
CN112521464A (zh)	2021-03-19
CN106103469A (zh)	2016-11-09
EA201691502A1 (ru)	2017-04-28
MX2016012538A (es)	2016-12-14
IL247328A0 (en)	2016-09-29

Publication	Publication Date	Title
IL252004A0 (en)	2017-06-29	Ether-substituted antibody
EP3172993A4 (en)	2018-02-21	Pillow
IL282104A (en)	2021-05-31	mutated staphylococcal antigens
GB201410520D0 (en)	2014-07-30	Antibody
ZA201604640B (en)	2019-03-27	Novel anti-netrin-1 antibody
EP3101310A4 (en)	2017-05-31	Damper device
IL248220A0 (en)	2016-11-30	Anti- nme antibody
EP3163117A4 (en)	2017-08-30	Damper device
EP3159574A4 (en)	2017-08-09	Damper device
GB201400819D0 (en)	2014-03-05	Mycobacterial antigen composition
PL2930270T3 (pl)	2019-11-29	Urządzenie tłumiące
IL247988A0 (en)	2016-11-30	Antibodies against hpa–1a
SG11201700922YA (en)	2017-03-30	Anti-orai1 antibody
SI3628731T1 (sl)	2021-08-31	Novo protitelo proti presepsinu
GB201409468D0 (en)	2014-07-09	Bacterium
GB201415602D0 (en)	2014-10-15	Streptococcal antigens
EP3124827A4 (en)	2017-04-05	Damper device
EP3106707A4 (en)	2017-11-29	Damper device
GB201418776D0 (en)	2014-12-03	Antibody
GB201413745D0 (en)	2014-09-17	Antibody
GB201411319D0 (en)	2014-08-06	Antibody
GB201407535D0 (en)	2014-06-11	Antibody Drug - Conjugates
GB201415298D0 (en)	2014-10-15	Antibody Formulations